The FDA has nar­rowed its search for a new leader of its Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search to three to four fi­nal can­di­dates, ac­cord­ing...

The Supreme Court re­stored mail or­der­ing of mifepri­s­tone re­vers­ing a fed­er­al ap­peals court’s stay.

The de­ci­sion Mon­daycame af­ter mak­ers of the pill asked for...

A new fla­vor of com­pa­ny is shak­ing up how biotechs are built.

In­stead of launch­ing with eye-pop­ping ear­ly-stage sci­ence or a new plat­form, there's a...

Ken Song has done it again.

The bio­phar­ma vet­er­an's all-out ef­fort to prove T cell en­gager­s' po­ten­tial in au­toim­mune dis­eases is get­ting picked up by...

A Swiss biotech with two ex­per­i­men­tal med­i­cines from Chi­na, plus an in-house dis­cov­ery team, has brought in $165 mil­lion to ad­vance in­to late-stage test­ing.

The...